Upon joining the trial, you will be required to provide written consent, confirming your understanding of the trial requirements and your willingness to comply with the procedures.

You will need to confirm your eligibility, which includes having completed certain stages of a previous trial or being offered participation due to specific circumstances.

An initial assessment will be conducted to ensure you meet all necessary criteria, including a negative pregnancy test for women of childbearing potential.

You will be informed about the importance of using an acceptable method of contraception during the trial.

You will receive the medication efgartigimod PH20 SC, which is a solution for injection administered subcutaneously (under the skin).

The frequency and dosage will be determined by the trial protocol, and you will be informed about the schedule for your injections.

You will attend regular study visits where various assessments will be conducted, including blood sampling to monitor for any significant laboratory abnormalities.

During these visits, your health and response to the medication will be closely monitored.

Throughout the trial, the incidence of any adverse events will be recorded, and your overall health will be assessed.

You will be asked to complete questionnaires about your quality of life, pain levels, treatment satisfaction, and any feelings of anxiety or depression.

You may be trained to self-administer the medication, or a caregiver may be instructed on how to assist you with the injections.

The percentage of patients performing self-administration will be monitored over time.

Upon completion of the trial, a final assessment will be conducted to evaluate your overall health and the effects of the medication.

You will be informed about any follow-up procedures or additional steps required after the trial ends.